Predicting response to liver cancer treatment
Part of Cancer, Digestive system clinical trials.
This study is looking at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer that can't be removed by surgery. The goal is to learn how to predict the best response using lab tests and CT scans.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with liver cancer (hepatocellular carcinoma, or HCC).
- You are currently taking or have taken atezolizumab (Tecentriq) combined with bevacizumab (Avastin).
- You are 18 years or older.
- You have a recent CT scan (with contrast) taken within the month before starting treatment.
- You do not have any other type of cancer right now.
- You are generally able to get out of bed and take care of yourself (your performance status is 2 or lower).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well a combination of liver-directed therapy and immunotherapy works for people with liver cancer that cannot be removed by surgery. It aims to find markers in your blood that might predict if the treatment will shrink the tumor enough to allow surgery later.
This trial looks at whether adding a procedure called TACE to standard immunotherapy (Atezolizumab plus Bevacizumab) works better for people with liver cancer that cannot be removed by surgery. It aims to create a model to predict who benefits most from this combination.
This study tries to predict how well your cancer responds early after starting a treatment called atezolizumab plus bevacizumab. If you qualify, your information may help doctors choose better treatments sooner for people with advanced liver cancer.
This trial looks at how well the combination of atezolizumab and bevacizumab works for people with advanced liver cancer that cannot be removed by surgery. Researchers will study blood samples to find markers that might predict how well the treatment works.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This study looks at how well the combination of atezolizumab and bevacizumab works for people with liver cancer that has come back or spread, based on real patient records from a hospital registry.
Hear when a new HCC - Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.